Literature DB >> 21292778

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Meletios Dimopoulos1, Robert Kyle, Jean-Paul Fermand, S Vincent Rajkumar, Jesus San Miguel, Asher Chanan-Khan, Heinz Ludwig, Douglas Joshua, Jayesh Mehta, Morie Gertz, Hervé Avet-Loiseau, Meral Beksaç, Kenneth C Anderson, Philippe Moreau, Seema Singhal, Hartmut Goldschmidt, Mario Boccadoro, Shaji Kumar, Sergio Giralt, Nikhil C Munshi, Sundar Jagannath.   

Abstract

A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β(2)-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21292778     DOI: 10.1182/blood-2010-10-299529

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  102 in total

1.  Using single protein biomarkers to predict health and disease in diverse patient populations: a new role for assessment of immunoglobulin free light chains.

Authors:  Mark T Drayson
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

2.  Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.

Authors:  Giuseppe Lucio Cascini; Carmela Falcone; Domenico Console; Antonino Restuccia; Marco Rossi; Antonello Parlati; Oscar Tamburrini
Journal:  Radiol Med       Date:  2013-06-26       Impact factor: 3.469

3.  [Unusual skin alterations in a 72-year-old patient with multiple myeloma].

Authors:  C Hart; S Wurm; C Hafner; R Andreesen; M Grube
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743

4.  Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma.

Authors:  Kosei Matsue; Hiroki Kobayashi; Yuya Matsue; Yoshiaki Abe; Kentaro Narita; Akihiro Kitadate; Masami Takeuchi
Journal:  Blood Adv       Date:  2018-05-08

5.  Imaginological characterization of multiple myeloma lesions of the jaws through cone-beam computed tomography.

Authors:  Thaiza Gonçalves Rocha; Édila Figuerêdo Feitosa; Ângelo Maiolino; Roberto José Pessoa de Magalhães Filho; Fábio Ribeiro Guedes; Sandra Regina Torres; Maria Augusta Visconti
Journal:  Oral Radiol       Date:  2019-06-19       Impact factor: 1.852

6.  Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.

Authors:  J Hillengass; M-A Weber; K Kilk; K Listl; B Wagner-Gund; M Hillengass; T Hielscher; A Farid; K Neben; S Delorme; O Landgren; H Goldschmidt
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 7.  Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.

Authors:  Uday Yanamandra; Navin Khattry; Shaji Kumar; Noopur Raje; Arihant Jain; Sundar Jagannath; Hari Menon; Lalit Kumar; Neelam Varma; Subhash Varma; Tapan Saikia; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-02       Impact factor: 0.900

Review 8.  [Management of osseous complications in multiple myeloma].

Authors:  K Zarghooni; S Hopf; P Eysel
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

Review 9.  The Critical Role of Imaging in the Management of Multiple Myeloma.

Authors:  Shahzad Raza; Siyang Leng; Suzanne Lentzsch
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

10.  Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.

Authors:  Tae-Dong Jeong; Chan-Jeoung Park; Hyoeun Shim; Seongsoo Jang; Hyun-Sook Chi; Dok Hyun Yoon; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Cheolwon Suh; Kyoo Hyung Lee
Journal:  Korean J Hematol       Date:  2012-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.